Related Experiment Video
Updated: Jan 19, 2026
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Protein Kinase CK2-A Putative Target for the Therapy of Diabetes Mellitus?
Emmanuel Ampofo1, Lisa Nalbach2, Michael D Menger3
1Institute for Clinical & Experimental Surgery, Saarland University, 66424 Homburg, Germany. emmanuel.ampofo@uks.eu.
Abstract:
Since diabetes is a global epidemic, the development of novel therapeutic strategies for the treatment of this disease is of major clinical interest. Diabetes is differentiated in two types: type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T1DM arises from an autoimmune destruction of insulin-producing β-cells whereas T2DM is characterized by an insulin resistance, an impaired insulin reaction of the target cells, and/or dysregulated insulin secretion. In the past, a growing number of studies have reported on the important role of the protein kinase CK2 in the regulation of the survival and endocrine function of pancreatic β-cells. In fact, inhibition of CK2 is capable of reducing cytokine-induced loss of β-cells and increases insulin expression as well as secretion by various pathways that are regulated by reversible phosphorylation of proteins. Moreover, CK2 inhibition modulates pathways that are involved in the development of diabetes and prevents signal transduction, leading to late complications such as diabetic retinopathy. Hence, targeting CK2 may represent a novel therapeutic strategy for the treatment of diabetes.
Insights
Targeting protein kinase CK2 may offer a new therapeutic strategy for diabetes. Inhibiting CK2 protects pancreatic beta-cells and improves insulin function, potentially treating both type 1 and type 2 diabetes.
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Diabetes mellitus (T1DM and T2DM) is a global health crisis requiring novel treatments.
- Pancreatic beta-cell survival and function are crucial for diabetes management.
- Protein kinase CK2 (CK2) has been implicated in regulating beta-cell function.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting protein kinase CK2 for diabetes treatment.
- To explore CK2's role in pancreatic beta-cell survival and insulin secretion.
Main Methods:
- Review of existing studies on CK2's role in beta-cell biology.
- Analysis of CK2 inhibition effects on cytokine-induced beta-cell loss.
- Examination of CK2's impact on insulin expression and secretion pathways.
Main Results:
- CK2 inhibition reduces cytokine-induced beta-cell death.
- CK2 inhibition enhances insulin expression and secretion.
- CK2 modulation affects diabetes-related pathways and prevents diabetic complications like retinopathy.
Conclusions:
- Targeting protein kinase CK2 presents a promising novel therapeutic strategy for diabetes.
- CK2 inhibition offers a potential approach to improve beta-cell function and mitigate diabetes complications.
Related Concept Videos
11:11Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
10:03A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
04:26Streptozocin Treatment: A Zebrafish Model of Type 1 Diabetes Mellitus
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
01:22Diabetes Mellitus: Type 2 and Gestational